I. Claesson

External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas

K. Partheen, G. Horvath, K. Sundfeldt, 2009, BMC Cancer.

Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.

L. Jacobsson, P. Bernhardt, R. Hultborn, 2006, International journal of radiation oncology, biology, physics.

Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.

L. Jacobsson, R. Hultborn, H. Andersson, 2006, Nuclear medicine and biology.

Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.

L. Jacobsson, A. Danielsson, R. Hultborn, 2007, International journal of radiation oncology, biology, physics.

In vitro effects of free 211At,211At-albumin and 211At-monoclonal antibody compared to external photon irradiation on two human cancer cell lines.

L. Jacobsson, R. Hultborn, H. Andersson, 2000, Anticancer research.

Single-cell irradiation from [211At] astatine-labeled C215 monoclonal antibody: improved estimates of radiosensitivity from measurements on cellular uptake and retention.

L. Jacobsson, R. Hultborn, T. Bäck, 2003, Anticancer Research.

Effects of the alpha-particle emitter At-211 and low-dose-rate gamma-radiation on the human cell line Colo-205 as studied with a growth assay.

L. Jacobsson, R. Hultborn, T. Bäck, 1998, Anticancer research.

Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.

L. Jacobsson, R. Hultborn, H. Andersson, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas

K. Partheen, G. Horvath, K. Sundfeldt, 2008, International journal of cancer.